Abstract
BACKGROUND: The risk factors for acute episodes of respiratory disease in current and former smokers who do not have COPD are unknown.
METHODS: Eight thousand two hundred forty-six non-Hispanic white and black current and former smokers in the Genetic Epidemiology of COPD (COPDGene) cohort had longitudinal follow-up (LFU) every 6 months to determine acute respiratory episodes requiring antibiotics or systemic corticosteroids, an ED visit, or hospitalization. Negative binomial regression was used to determine the factors associated with acute respiratory episodes. A Cox proportional hazards model was used to determine adjusted hazard ratios (HRs) for time to first episode and an acute episode of respiratory disease risk score.
RESULTS: At enrollment, 4,442 subjects did not have COPD, 658 had mild COPD, and 3,146 had moderate or worse COPD. Nine thousand three hundred three acute episodes of respiratory disease and 2,707 hospitalizations were reported in LFU (3,044 acute episodes of respiratory disease and 827 hospitalizations in those without COPD). Major predictors included acute episodes of respiratory disease in year prior to enrollment (HR, 1.20; 95% CI, 1.15-1.24 per exacerbation), airflow obstruction (HR, 0.94; 95% CI, 0.91-0.96 per 10% change in % predicted FEV 1 ), and poor health-related quality of life (HR, 1.07; 95% CI, 1.06-1.08 for each 4-unit increase in St. George's Respiratory Questionnaire score). Risks were similar for those with and without COPD.
CONCLUSIONS: Although acute episode of respiratory disease rates are higher in subjects with COPD, risk factors are similar, and at a population level, there are more episodes in smokers without COPD.
Original language | English (US) |
---|---|
Pages (from-to) | 941-950 |
Number of pages | 10 |
Journal | CHEST |
Volume | 146 |
Issue number | 4 |
DOIs | |
State | Published - Oct 1 2014 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
- Cardiology and Cardiovascular Medicine
Fingerprint
Dive into the research topics of 'Prediction of acute respiratory disease in current and former smokers with and without COPD'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Prediction of acute respiratory disease in current and former smokers with and without COPD. / Bowler, Russell P.; Kim, Victor; Regan, Elizabeth; Williams, André A.A.; Santorico, Stephanie A.; Make, Barry J.; Lynch, David A.; Hokanson, John E.; Washko, George R.; Bercz, Peter; Soler, Xavier; Marchetti, Nathaniel; Criner, Gerard J.; Ramsdell, Joe; Han, Mei Lan K.; Demeo, Dawn; Anzueto, Antonio; Comellas, Alejandro; Crapo, James D.; Dransfield, Mark; Wells, J. Michael; Hersh, Craig P.; MacIntyre, Neil; Martinez, Fernando; Nath, Hrudaya P.; Niewoehner, Dennis; Sciurba, Frank; Sharafkhaneh, Amir; Silverman, Edwin K.; Van Beek, Edwin J.R.; Wilson, Carla; Wendt, Christine; Wise, Robert A.; Curtis, Jeffrey; Kazerooni, Ella; Hanania, Nicola; Alapat, Philip; Bandi, Venkata; Guntupalli, Kalpalatha; Guy, Elizabeth; Lunn, William; Mallampalli, Antara; Trinh, Charles; Atik, Mustafa; Jacobson, Francine; Barr, R. Graham; Thomashow, Byron; Austin, John; Washington, Lacey; McAdams, H. Page; Rosiello, Richard; Bresnahan, Timothy; McEvoy, Charlene; Tashjian, Joseph; Hansel, Nadia; Brown, Robert; Casaburi, Richard; Porszasz, Janos; Fischer, Hans; Budoff, Matt; Allen, Tadashi; Rice, Kathryn; Foreman, Marilyn; Westney, Gloria; Berkowitz, Eugene; Friedlander, Adam; Meoni, Eleonora; Satti, Aditi; Mamary, A. James; Steiner, Robert; Dass, Chandra; Bailey, William; Gerald, Lynn; Ferguson, Paul; Friedman, Paul; McLennan, Geoffrey; Van Beek, Edwin J.R.; Thompson, Deborah; Weissfeld, Joel; Fuhrman, Carl; Bon, Jessica; Adams, Sandra; Orozco, Carlos; Restrepo, C. Santiago; Mumbower, Amy; Samet, Jonathan; Willis, Amy; Stinson, Douglas; Beaty, Terri; Klanderman, Barbara; Laird, Nan; Lange, Christoph; Ionita, Iuliana; Schroeder, Joyce; Newell, John; Reilly, John; Coxson, Harvey; Judy, Philip; Man, Eric Hoff; Estepar, Raul San Jose; Leek, Rebecca; Zach, Jordan; Kluiber, Alex; Rodionova, Anastasia; Mann, Tanya; Crapo, Robert; Jensen, Robert; Farzadegan, Homayoon; Murphy, James; Everett, Douglas.
In: CHEST, Vol. 146, No. 4, 01.10.2014, p. 941-950.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Prediction of acute respiratory disease in current and former smokers with and without COPD
AU - Bowler, Russell P.
AU - Kim, Victor
AU - Regan, Elizabeth
AU - Williams, André A.A.
AU - Santorico, Stephanie A.
AU - Make, Barry J.
AU - Lynch, David A.
AU - Hokanson, John E.
AU - Washko, George R.
AU - Bercz, Peter
AU - Soler, Xavier
AU - Marchetti, Nathaniel
AU - Criner, Gerard J.
AU - Ramsdell, Joe
AU - Han, Mei Lan K.
AU - Demeo, Dawn
AU - Anzueto, Antonio
AU - Comellas, Alejandro
AU - Crapo, James D.
AU - Dransfield, Mark
AU - Wells, J. Michael
AU - Hersh, Craig P.
AU - MacIntyre, Neil
AU - Martinez, Fernando
AU - Nath, Hrudaya P.
AU - Niewoehner, Dennis
AU - Sciurba, Frank
AU - Sharafkhaneh, Amir
AU - Silverman, Edwin K.
AU - Van Beek, Edwin J.R.
AU - Wilson, Carla
AU - Wendt, Christine
AU - Wise, Robert A.
AU - Curtis, Jeffrey
AU - Kazerooni, Ella
AU - Hanania, Nicola
AU - Alapat, Philip
AU - Bandi, Venkata
AU - Guntupalli, Kalpalatha
AU - Guy, Elizabeth
AU - Lunn, William
AU - Mallampalli, Antara
AU - Trinh, Charles
AU - Atik, Mustafa
AU - Jacobson, Francine
AU - Barr, R. Graham
AU - Thomashow, Byron
AU - Austin, John
AU - Washington, Lacey
AU - McAdams, H. Page
AU - Rosiello, Richard
AU - Bresnahan, Timothy
AU - McEvoy, Charlene
AU - Tashjian, Joseph
AU - Hansel, Nadia
AU - Brown, Robert
AU - Casaburi, Richard
AU - Porszasz, Janos
AU - Fischer, Hans
AU - Budoff, Matt
AU - Allen, Tadashi
AU - Rice, Kathryn
AU - Foreman, Marilyn
AU - Westney, Gloria
AU - Berkowitz, Eugene
AU - Friedlander, Adam
AU - Meoni, Eleonora
AU - Satti, Aditi
AU - Mamary, A. James
AU - Steiner, Robert
AU - Dass, Chandra
AU - Bailey, William
AU - Gerald, Lynn
AU - Ferguson, Paul
AU - Friedman, Paul
AU - McLennan, Geoffrey
AU - Van Beek, Edwin J.R.
AU - Thompson, Deborah
AU - Weissfeld, Joel
AU - Fuhrman, Carl
AU - Bon, Jessica
AU - Adams, Sandra
AU - Orozco, Carlos
AU - Restrepo, C. Santiago
AU - Mumbower, Amy
AU - Samet, Jonathan
AU - Willis, Amy
AU - Stinson, Douglas
AU - Beaty, Terri
AU - Klanderman, Barbara
AU - Laird, Nan
AU - Lange, Christoph
AU - Ionita, Iuliana
AU - Schroeder, Joyce
AU - Newell, John
AU - Reilly, John
AU - Coxson, Harvey
AU - Judy, Philip
AU - Man, Eric Hoff
AU - Estepar, Raul San Jose
AU - Leek, Rebecca
AU - Zach, Jordan
AU - Kluiber, Alex
AU - Rodionova, Anastasia
AU - Mann, Tanya
AU - Crapo, Robert
AU - Jensen, Robert
AU - Farzadegan, Homayoon
AU - Murphy, James
AU - Everett, Douglas
N1 - Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Kim has participated in clinical trials sponsored by Boehringer-Ingelheim, GlaxoSmithKline, MedImmune, and Roche Pharmaceuticals. Dr Make has participated in advisory boards for AstraZeneca; Boehringer-Ingelheim; GlaxoSmithKline; Pfizer Inc; Sunovion Pharmaceuticals Inc; Forest Pharmaceuticals, Inc; Merck; Ikaria; Philips Respironics; Aerocrine; Theravance, Inc; and Covidien Ltd. Dr Lynch is a consultant to Perceptive Imaging, Inc; Boehringer-Ingelheim; Genentech; Gilead Sciences, Inc; Veracyte; Intermune; and MedImmune. Dr Han has participated in research sponsored by GlaxoSmithKline with monies paid to her institution. She has consulted for GlaxoSmithKline, MedImmune, and Ikaria and has participated on speakers bureaus for GlaxoSmithKline; Boehringer-Ingelheim; Pfizer Inc; Forest Pharmaceuticals, Inc; Novartis; and Grifols. Dr Comellas has consulted for Vida Diagnostics, Inc. Dr Dransfield has served as a consultant for GlaxoSmithKline, Boehringer-Ingelheim, and Ikaria. His institution has received research grant support from the National Heart, Lung and Blood Institute; GlaxoSmithKline; and Forest Pharmaceuticals, Inc; and has received contracted support for enrollment in clinical trials from Aeris Therapeutics; Boehringer-Ingelheim; Boston Scientific; Centocor Ortho Biotech, Inc; GlaxoSmithKline; Forest Pharmaceuticals, Inc; Otsuka America Pharmaceutical, Inc; Pearl Therapeutics; Pfizer Inc; and Pulmonx. Dr Hersh has received lecture fees from Novartis and has served as a consultant to CSL Behring. Dr MacIntyre has received NIH funding for the COPDGene project. Dr Martinez has participated in steering committees in COPD or idiopathic pulmonary fibrosis sponsored by Actelion Pharmaceuticals Ltd; Bayer; Centocor Ortho Biotech, Inc; Forest Pharmaceuticals, Inc; Gilead Sciences, Inc; Jannsen Pharmaceuticals, Inc; GlaxoSmithKline, Nycomed/Takeda; and Promedior. He has participated in advisory boards for COPD or idiopathic pulmonary fibrosis for Amgen; AstraZeneca; Carden Jennings Publishing Co, Ltd; CardioMEMS; CSA Medical Inc; Forest Pharmaceuticals, Inc; Ikaria; Jannsen Pharmaceuticals, Inc; MedImmune; Merck; Pearl Therapeutics; Nycomed/Takeda; Pfizer Inc; and Vertex. Dr Martinez has participated on data safety monitoring committees sponsored by GlaxoSmithKline and Stromedix Inc. He has helped with Food and Drug Administration presentations for Boehringer-Ingelheim, GlaxoSmithKline, and Ikaria. He has spoken on COPD for Bayer; Forest Pharmaceuticals, Inc; GlaxoSmithKline; Nycomed/Takeda; and Prescott Medical Communications Group. He has participated in advisory teleconferences sponsored by the American Institute for Research, Axon, Cory Path, Grey Healthcare Group, Merion, and Sudler & Hennessey. He has received royalties from Informa Healthcare. Dr Niewoehner has received fees from Boehringer-Ingelheim, Novartis, and GlaxoSmithKline for serving on end point committees of clinical trials. He has received fees from AstraZeneca and Gilead Sciences, Inc, for serving on advisory boards. Dr Sciurba has served as a pharmaceutical consultant. Dr Silverman has received grant support from GlaxoSmithKline for studies of COPD genetics. Drs Bowler, Regan, Willams, Santorico, Hokanson, Washko, Bercz, Soler, Marchetti, Criner, Ramsdell, Demeo, Anzueto, Crapo, Wells, Nath, Sharafkhaneh, van Beek, Wendt, and Wise, and Ms Wilson have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. Publisher Copyright: © 2014 American College of Chest Physicians.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - BACKGROUND: The risk factors for acute episodes of respiratory disease in current and former smokers who do not have COPD are unknown.METHODS: Eight thousand two hundred forty-six non-Hispanic white and black current and former smokers in the Genetic Epidemiology of COPD (COPDGene) cohort had longitudinal follow-up (LFU) every 6 months to determine acute respiratory episodes requiring antibiotics or systemic corticosteroids, an ED visit, or hospitalization. Negative binomial regression was used to determine the factors associated with acute respiratory episodes. A Cox proportional hazards model was used to determine adjusted hazard ratios (HRs) for time to first episode and an acute episode of respiratory disease risk score.RESULTS: At enrollment, 4,442 subjects did not have COPD, 658 had mild COPD, and 3,146 had moderate or worse COPD. Nine thousand three hundred three acute episodes of respiratory disease and 2,707 hospitalizations were reported in LFU (3,044 acute episodes of respiratory disease and 827 hospitalizations in those without COPD). Major predictors included acute episodes of respiratory disease in year prior to enrollment (HR, 1.20; 95% CI, 1.15-1.24 per exacerbation), airflow obstruction (HR, 0.94; 95% CI, 0.91-0.96 per 10% change in % predicted FEV 1 ), and poor health-related quality of life (HR, 1.07; 95% CI, 1.06-1.08 for each 4-unit increase in St. George's Respiratory Questionnaire score). Risks were similar for those with and without COPD.CONCLUSIONS: Although acute episode of respiratory disease rates are higher in subjects with COPD, risk factors are similar, and at a population level, there are more episodes in smokers without COPD.
AB - BACKGROUND: The risk factors for acute episodes of respiratory disease in current and former smokers who do not have COPD are unknown.METHODS: Eight thousand two hundred forty-six non-Hispanic white and black current and former smokers in the Genetic Epidemiology of COPD (COPDGene) cohort had longitudinal follow-up (LFU) every 6 months to determine acute respiratory episodes requiring antibiotics or systemic corticosteroids, an ED visit, or hospitalization. Negative binomial regression was used to determine the factors associated with acute respiratory episodes. A Cox proportional hazards model was used to determine adjusted hazard ratios (HRs) for time to first episode and an acute episode of respiratory disease risk score.RESULTS: At enrollment, 4,442 subjects did not have COPD, 658 had mild COPD, and 3,146 had moderate or worse COPD. Nine thousand three hundred three acute episodes of respiratory disease and 2,707 hospitalizations were reported in LFU (3,044 acute episodes of respiratory disease and 827 hospitalizations in those without COPD). Major predictors included acute episodes of respiratory disease in year prior to enrollment (HR, 1.20; 95% CI, 1.15-1.24 per exacerbation), airflow obstruction (HR, 0.94; 95% CI, 0.91-0.96 per 10% change in % predicted FEV 1 ), and poor health-related quality of life (HR, 1.07; 95% CI, 1.06-1.08 for each 4-unit increase in St. George's Respiratory Questionnaire score). Risks were similar for those with and without COPD.CONCLUSIONS: Although acute episode of respiratory disease rates are higher in subjects with COPD, risk factors are similar, and at a population level, there are more episodes in smokers without COPD.
UR - http://www.scopus.com/inward/record.url?scp=84907942900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907942900&partnerID=8YFLogxK
U2 - 10.1378/chest.13-2946
DO - 10.1378/chest.13-2946
M3 - Article
C2 - 24945159
AN - SCOPUS:84907942900
VL - 146
SP - 941
EP - 950
JO - Diseases of the chest
JF - Diseases of the chest
SN - 0012-3692
IS - 4
ER -